ClinicalTrials.gg

Program

Rocuronium

Also written as “Rocuronium bromide (Zemuron)”, “rocuronium” and “Rocuronium (0.6mg/kg)”.

Its studies are mostly in Patient Satisfaction, led by 4 companies.

Furthest: phase 4, since Apr 2, 201511 company-led studies, 1 open or runningNext primary completion: Jun 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck80 open or runningphase 4since Apr 2, 2015Jul 26, 2005none ahead
Amckaus PTY11 open or runningphase 2since Apr 20, 2026Apr 20, 2026Jun 30, 2027phase 2 · NCT07595393
Dr. Horst Schmidt Klinik10 open or runningno phasesince Jul 9, 2013Jul 9, 2013none ahead
Medtronic10 open or runningno phasesince Sep 22, 2011Sep 22, 2011none ahead

Also a collaborator on its studies: novotech-australia-pty-limited.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 26, 2005First studies: 2 phase 3 studies in AnesthesiaNew to MerckMerck · NCT00124735, NCT00124722
  2. May 14, 20072 phase 3 studies in Anesthesia, GeneralMerck · NCT00473694, NCT00474253
  3. Oct 31, 2007Phase 2 study in Anesthesia, GeneralMerck · NCT00552617 · 100 enrolled
  4. Sep 10, 2008Phase 3 study in Neuromuscular BlockadeMerck · NCT00751179 · 161 enrolled
  5. Jul 23, 2009Phase 3 study in AnesthesiaMerck · NCT00970762 · 90 enrolled
  6. Sep 22, 2011Medtronic's first study: no phase study in AnesthesiaNew to MedtronicMedtronic · NCT01450813 · 80 enrolled · United States
  7. Jul 9, 2013Dr. Horst Schmidt Klinik's first study: no phase study in FasciculationNew to Dr. Horst Schmidt KlinikDr. Horst Schmidt Klinik · NCT01902641 · 105 enrolled · Germany
  8. Apr 2, 2015Phase 4 study in Neuromuscular BlockadeMerck · NCT02410590
  9. Apr 20, 2026Amckaus PTY's first study: phase 2 study in Reversing Vecuronium-Induced Neuromuscular Blockade in Patients Undergoing General Anesthesia SurgeryNew to Amckaus PTYAmckaus PTY · NCT07595393 · 64 planned

Ahead

  1. Jun 30, 2027Primary completion: phase 2 study in Reversing Vecuronium-Induced Neuromuscular Blockade in Patients Undergoing General Anesthesia SurgeryAmckaus PTY · NCT07595393

TargetBeta

“Muscle-type nicotinic acetylcholine receptor antagonist”ChEMBL 37, by rule

Other programs on the same 5 targets

ProgramCompanyFurthest phaseStudies
vecuroniumruleMerckphase 44

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07595393Reversing Vecuronium-Induced Neuromuscular Blockade in Patients Undergoing General Anesthesia Surgery2Not yet recruitingAmckaus PTYJun 30, 202764
NCT02410590Neuromuscular Blockade4WithdrawnMerckOct 20160
NCT01902641Fasciculation · Germany–CompletedDr. Horst Schmidt KlinikMar 2012105
NCT01450813Anesthesia · United States–CompletedMedtronicDec 201380
NCT00970762Anesthesia3CompletedMerckFeb 200490
NCT00751179Neuromuscular Blockade3CompletedMerckDec 2009161
NCT00552617Anesthesia, General2CompletedMerckAug 31, 2006100
NCT00474253Anesthesia, General3CompletedMerckAug 22, 2006115
NCT00473694Anesthesia, General3CompletedMerckNov 6, 2006182
NCT00124735Anesthesia3CompletedMerckAug 2007149
NCT00124722Anesthesia3CompletedMerckJul 2007207

How it is read

Names in the registry

  • “Rocuronium”, 4 entries
  • “Rocuronium bromide (Zemuron)”, 3 entries
  • “rocuronium”, 2 entries
  • “Rocuronium (0.6mg/kg)”, 1 entry
  • “Rocuronium 0.2 mg/kg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.